Zealand Pharma A/S

ZEAL

DK0060257814

Biotechnology & Medical Research

Market Closed - Nasdaq Copenhagen Other stock markets 11:20:00 2025-07-07 EDT			5-day change	1st Jan Change
362.80 ^DKK	-3.25%		+0.83%	-49.29%

07-01	European shares end marginally lower as markets gauge trade talks, US tax bill	RE
07-01	BNP Paribas Exane Begins Zealand Pharma Coverage at Outperform	MT

Goldman Sachs lowers target price for Zealand Pharma to DKK 806 (USD 873), reiterates buy rating - BN

Published on 2025-05-09 at 00:24

Go to the original article.
Legal disclaimer

Latest news about Zealand Pharma A/S

European shares end marginally lower as markets gauge trade talks, US tax bill	07-01	RE
BNP Paribas Exane Begins Zealand Pharma Coverage at Outperform	07-01	MT
Berenberg Cuts Zealand Pharma's Price Target Amid Increased Competition	07-01	MT
Kempen Downgrades Zealand Pharma to Neutral, Cuts PT	06-27	MT
Kempen Downgrades Zealand Pharma to Neutral (Buy), Target Price 450 Danish Kroner - BN	06-27	FW
Berenberg Lowers Price Target for Zealand Pharma to 850 Danish Kroner (1,050), Reiterates Buy - BN	06-27	FW
Goldman Sachs Raises Price Target for Zealand Pharma to 820 Danish Kroner, Reiterates Buy - BN	06-25	FW
Zealand Pharma A/S(CPSE:ZEAL) dropped from OMX Nordic 40 Index	06-19	CI
Zealand Pharma Announces Positive Results From 28-Week Phase 1B Dapiglutide Trial	06-18	RE
Zealand Pharma A/S Announces Positive Topline Clinical Results from Part 2 of a Phase 1b Multiple Ascending Dose Trial	06-18	CI
Eli Lilly's experimental obesity drug shows over 11% weight loss in early trial	06-13	RE
Zealand Pharma A/S Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-11-2025 04:00 PM	06-11
Metsera rises as experimental weight-loss drug shows promise in small early-stage trial	06-10	RE
Zealand Pharma A/S Submits Marketing Authorization Application to the European Medicines Agency for Glepaglutide in Short Bowel Syndrome	06-02	CI
Zealand Pharma Files EU Marketing Authorization Application for Short Bowel Syndrome Treatment	06-02	MT
Zealand Pharma Applies To EMA For Marketing Authorization For Glepaglutide In Short Bowel Syndrome	06-02	RE
European stocks recover after Trump delays EU tariffs in hopes of deal	05-26	RE
Danish Biotech Zealand Pharma Names Chief Development Officer	05-20	MT
Zealand Pharma A/S Appoints Steven Johnson as Chief Development Officer	05-19	CI
Deutsche Bank lowers its target price for Zealand Pharma to 485 Danish kroner (750), reiterates hold	05-19	FW
Weight-loss drug developers line up to tap lucrative market as competition heats up	05-16	RE
Denmark says Trump's drug pricing order is a step in the wrong direction	05-16	RE
Zealand Pharma A/S Presents at BofA Securities 2025 Healthcare Conference, May-14-2025 08:00 AM	05-14
Zealand Pharma A/S Announces Closing of Collaboration and License Agreement with Roche	05-09	CI
DNB lowers target price for Zealand Pharma to DKK 950 (1,000), reiterates buy recommendation - BN	05-09	FW

Zealand Pharma A/S is specialized in the research and development of peptide drugs mainly for the treatment of diabetes, rare diseases and obesity. At the end of 2023, the Group had a portfolio of 7 products in clinical development (including 3 in phase III, 3 in phase II and 1 in phase I), and 3 products in preclinical development.

Employees

385

Sector

Biotechnology & Medical Research

Calendar

08-14 - Q2 2025 Earnings Release

More about the company